Orexin-A

What is Orexin-A?

Orexin-A (also called hypocretin-1) is a 33-amino-acid neuropeptide made by a small population of neurons in the lateral and posterior hypothalamus. It is cut from the same precursor protein as its sister peptide orexin-B, carries two internal disulfide bonds, and activates both orexin receptors (OX1R and OX2R) to keep the brain's arousal systems switched on during the day and to stabilize the boundary between sleep and wakefulness. In narcolepsy type 1, 85–95% of these neurons are lost and orexin-A becomes undetectable in the cerebrospinal fluid of most patients. Three different things get called 'orexin' online, and this page keeps them apart. The first is the natural peptide and its biology. The second is orexin-A given as an experimental or research-chemical preparation, usually a nasal spray: in people this has been tested only in four small single-dose studies of 7 to 14 participants each, with modest effects on REM sleep, attention, and smell in narcolepsy and on sympathetic nerve activity in healthy men, and it is not approved anywhere. The third is the orexin drugs, which are small molecules, not peptides: oral orexin receptor 2 agonists such as Takeda's oveporexton (Orzeyful; FDA-approved for adults with narcolepsy type 1 in August 2026, with launch pending DEA scheduling) and Alkermes' alixorexton (ALKS 2680; in Phase 3), and the orexin receptor antagonists suvorexant, lemborexant, and daridorexant, which are approved for insomnia.

What Orexin-A Is Investigated For

Orexin-A is the endogenous wakefulness-promoting neuropeptide whose loss causes narcolepsy type 1, and research interest centers on replacement therapy for narcolepsy, promotion of alertness and wakefulness, and to a lesser extent metabolic and appetite regulation. The strongest mechanistic case is in narcolepsy type 1 — where orexin deficiency is the defining pathology — and three small single-dose intranasal studies (7–14 patients each) reported modest acute effects on REM sleep stability, attention, and smell in narcoleptic patients, not a demonstrated increase in wakefulness. The translational future of orexin pharmacology has shifted decisively to oral small-molecule OX2R agonists, which are separate drugs rather than forms of the peptide: the FDA approved Takeda's oveporexton (TAK-861, brand name Orzeyful) for adults with narcolepsy type 1 in an August 5, 2026 action letter after two positive Phase 3 trials (Dauvilliers et al., NEJM September 2026, PMID 42714024), with the approval taking legal effect, and the drug becoming marketable, only once the DEA publishes its controlled-substance scheduling, and Alkermes' alixorexton reported a positive Vibrance-1 Phase 2 RCT in Lancet Neurology August 2026 (PMID 42636845) with placebo-corrected MWT gains of ~22–26 minutes across 4/6/8 mg doses, meaningfully broadening the OX2R class beyond a single molecule; alixorexton is now in Phase 3. Peptide-based orexin-A as a chronic replacement therapy has not advanced through controlled long-term human trials and is now competing against a much more practical and validated small-molecule path. Use in healthy adults for cognition or alertness has no rigorous clinical basis, and exogenous augmentation raises plausible cardiovascular and sympathetic concerns given orexin's pressor effects — with the additional caveat that a 2026 Analytical Chemistry LC-MS/MS methods paper (PMID 42118575) demonstrated that widely-cited plasma/serum orexin biomarker levels are analytical artifacts, so the peripheral-orexin correlation literature must be read with far greater caution than the pre-2026 field assumed. Active drug-development target, not an established therapy.

History & Discovery

Orexin-A — also called hypocretin-1 — was discovered in 1998 by two independent research groups within weeks of each other. Luis de Lecea and J. Gregor Sutcliffe at the Scripps Research Institute identified the peptides via subtractive hybridization for hypothalamic-specific transcripts and named them 'hypocretins' for their hypothalamic origin and structural relationship to the secretin peptide family. Almost simultaneously, Takeshi Sakurai and Masashi Yanagisawa at UT Southwestern identified the same peptides as ligands for orphan G-protein-coupled receptors and named them 'orexins,' from the Greek for appetite, based on their initial observation that intracerebroventricular injection increased food intake in rats. Both names persist in the literature; 'orexin' tends to dominate clinical neurology and 'hypocretin' tends to dominate basic neuroscience. The field's defining moment came two years later. In 2000, Emmanuel Mignot's group at Stanford reported that hypocretin was undetectable in the cerebrospinal fluid of seven of nine people with narcolepsy (Nishino et al., Lancet) and that hypocretin peptides were globally absent in narcoleptic brains (Peyron et al., Nature Medicine), and Jerome Siegel's group at UCLA found an 85–95% reduction in the number of hypocretin neurons (Thannickal et al., Neuron). That single finding redefined narcolepsy type 1 as an orexin-deficiency disorder and reframed the orexin system as a therapeutically tractable target for both wake-promoting and sleep-promoting drug development. The first wave of clinical translation went in the antagonist direction: dual orexin receptor antagonists (DORAs) — suvorexant, lemborexant, daridorexant — became approved insomnia drugs in the 2010s and early 2020s. The second wave, now the dominant area of clinical work, is in orexin agonists — small molecules rather than the peptide. Takeda's oveporexton (TAK-861) succeeded in two 12-week Phase 3 trials, First Light and Radiant Light (NEJM, September 2026, PMID 42714024), and on August 5, 2026 the FDA approved it as Orzeyful tablets for adults with narcolepsy type 1, the first orexin receptor 2 (OX2R) agonist to reach approval; because FDA recommended controlled-substance scheduling, the approval takes effect and the drug can launch only once the DEA publishes its scheduling notice. Alkermes reported a positive Phase 2 for alixorexton (Vibrance-1, Lancet Neurology August 2026, PMID 42636845) with placebo-corrected MWT gains of roughly 22–26 minutes across 4/6/8 mg dose arms — the second Phase 2-positive OX2R agonist, broadening the class beyond a single molecule — and began its Phase 3 Brilliance trials in 2026. Centessa's ORX750 remains in development. Intranasal orexin-A as a peptide replacement therapy was tested in narcolepsy in three small single-dose studies between 2008 and 2014 but has been comprehensively overtaken by the small-molecule oral agonist program. Separately, a 2026 Analytical Chemistry paper (PMID 42118575) established that widely-reported plasma and serum orexin-A concentrations are analytical artifacts — real peripheral concentrations are below the limit of detection — invalidating the interpretability of much of the pre-2026 'peripheral orexin as biomarker' clinical literature.

How It Works

Orexin-A is the brain's 'wake-up signal.' It activates arousal centers throughout the brain, keeping you alert and awake. When orexin neurons are destroyed (as in narcolepsy), people experience uncontrollable sleepiness.

Orexin-A binds to both OX1R and OX2R (orexin receptors 1 and 2), which are GPCRs expressed widely in the brain including the locus coeruleus, tuberomammillary nucleus, raphe nuclei, and ventral tegmental area. It activates noradrenergic, histaminergic, serotonergic, and dopaminergic arousal systems. OX2R is particularly important for sleep-wake regulation. Orexin-A also regulates the HPA axis, sympathetic tone, and energy metabolism. Structurally it is a 33-residue peptide with two intramolecular disulfide bonds, an N-terminal pyroglutamate, and a C-terminal amide; orexin-B, cut from the same precursor, is 28 residues long with no disulfide bonds. OX1R binds orexin-A with higher affinity than orexin-B, whereas OX2R responds to both.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Orexin-A:

• 01Chronic intranasal orexin-A safety and efficacy in narcolepsy — three small single-dose studies exist, but no repeat-dose or long-term replacement-therapy trial has been run, and the small-molecule OX2R-agonist path (oveporexton FDA-approved in August 2026 after two Phase 3 trials, PMID 42714024; alixorexton in Phase 3 after a positive Phase 2, PMID 42636845) has effectively displaced the peptide-replacement rationale.
• 02Whether peptide-based orexin-A retains any niche given the OX2R-agonist class validation — most plausibly in specialty settings where oral OX2R agonist tolerability, cost, or availability is a limiter; no head-to-head trials exist.
• 03How much of the pre-2026 peripheral-orexin biomarker literature survives the finding that plasma/serum orexin-A concentrations reported in the ng/mL range are analytical artifacts (Cao et al., Anal Chem 2026, PMID 42118575) — a systematic re-audit of prior claims linking peripheral orexin-A to cardiovascular, metabolic, and hormonal outcomes is warranted.
• 04Use in narcolepsy type 2 and idiopathic hypersomnia — most data is in narcolepsy type 1 (orexin-deficient by definition), and whether exogenous orexin helps conditions where the orexin system is intact is unclear.
• 05Cardiovascular safety with chronic use — orexin's sympathoexcitatory effects raise long-term cardiovascular concerns that have not been studied across years of replacement.
• 06Use in healthy adults for cognition or alertness — there is no rigorous clinical evidence that exogenous orexin-A meaningfully enhances wakefulness or cognition in non-deficient individuals, and the safety basis for off-label use is absent.
• 07Reproductive, pediatric, and pregnancy data — no studies in any of these populations.

Forms & Administration

Orexin-A peptide: intranasal spray in research studies only. It is not sold as an approved product anywhere, and research-chemical vials are not made for human use. Like other peptides it would be digested if swallowed, and human studies used the nasal route because it can carry peptides toward the brain along olfactory and trigeminal pathways. The orexin drugs are different molecules taken as tablets: oveporexton (FDA-approved in August 2026 for narcolepsy type 1, launch pending DEA scheduling) and the insomnia drugs suvorexant, lemborexant, and daridorexant.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Orexin-A is not approved for any therapeutic indication anywhere. It is a research peptide and a target of active drug development, not a treatment. Self-administered intranasal orexin-A from research-chemical sources carries unknown content, unknown sterility, and no dose-response basis in humans.

Timeline of Effects

Common Questions

Who Orexin-A Is NOT For

Drug & Supplement Interactions

Documented clinical drug interactions for orexin-A in humans are limited because human use is limited. The most concrete interaction is conceptual rather than empirical: dual orexin receptor antagonists (DORAs — suvorexant, lemborexant, daridorexant) are designed to block exactly the receptors orexin-A activates. Co-use would be pharmacologically self-defeating and is not described in any clinical context. Patients on a DORA for insomnia should not be exposed to exogenous orexin-A. With stimulants and other wake-promoting agents (modafinil, armodafinil, amphetamines, methylphenidate, solriamfetol, pitolisant), the additive arousal and cardiovascular load is plausible but not formally characterized. Cardiovascular stimulation from orexin-A on top of these drugs could produce additive blood pressure and heart rate effects. With antihypertensives and rate-control medications, orexin-A's sympathetic activation could partially offset their effect. With opioids and benzodiazepines (which suppress orexin signaling indirectly via central depression), the interaction direction is unpredictable in humans. As with any peptide of unverified clinical pharmacology, patients on regular medications should disclose any orexin-A use to their prescriber. Absence of documented interaction reflects absence of human use rather than absence of risk.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions